Q-omics provides the consensus-scored MYL8P profile across patient tissues and cancer cell-line models. MYL8P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MYL8P is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, MYL8P RNA expression shows 5,971 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight ACC, LUSC, and UCEC as cancer lineages where MYL8P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYL8P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYL8P survival associations across molecular data types. MYL8P RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYL8P RNA expression–survival associations across cancer types. High MYL8P expression shows unfavorable associations in ACC, BLCA, LUSC, LUAD and READ, but favorable associations in DLBC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MYL8P RNA expression.
This table summarizes MYL8P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MYL8P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYL8P shows lower tumor expression in LUSC and higher tumor expression in BLCA, KIRC and LIHC. The LUSC box plot shows higher MYL8P RNA expression in normal versus tumor tissue (log2 FC = −0.216, t-test p < 0.001).
This table shows molecular features associated with MYL8P in patient tissues and cancer cell lines. In patient samples, MYL8P shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
